ESPR Esperion Therapeutics Inc.

47.08
+2.32  (+5%)
Previous Close 44.76
Open 44.87
Price To Book 18.76
Market Cap 1,286,574,416
Shares 27,327,409
Volume 609,094
Short Ratio
Av. Daily Volume 385,730
Stock charts supplied by TradingView

NewsSee all news

  1. Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions

    ANN ARBOR, Mich., Nov. 17, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that pooled analyses from four Phase 3 clinical studies of bempedoic acid were presented at the American Heart Association

  2. Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results

     –  Study 2 Demonstrated that Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP – –  Over 52-Weeks, Overall Adverse Events in the Bempedoic Acid Treatment Arm were Comparable to Placebo – – Bempedoic

  3. Esperion to Participate in Upcoming Investor Conferences

    ANN ARBOR, Mich., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), today announced that the company will participate in fireside chats at the following conferences: Credit Suisse 28th Annual Healthcare

  4. Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results

    ANN ARBOR, Mich., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the third quarter ended September 30, 2019. "The

  5. Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions

    ANN ARBOR, Mich., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that pooled analyses from four Phase 3 clinical trials of bempedoic acid will be presented at the American Heart Association

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

PDUFA date February 26, 2020.
Bempedoic Acid/ Ezetimibe
Hypercholesterolemia
PDUFA date February 21, 2020.
Bempedoic acid
Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins
Phase 2 trial met primary endpoint - August 29, 2019.
Bempedoic Acid/ Ezetimibe (1002-058)
LDL-C and type 2 diabetes
Phase 3 completion of enrolment announced September 5, 2019. Trial to be completed in 2H 2022.
Bempedoic Acid (ETC-1002) CLEAR Outcomes
Cardiovascular Diseases

Latest News

  1. Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions

    ANN ARBOR, Mich., Nov. 17, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that pooled analyses from four Phase 3 clinical studies of bempedoic acid were presented at the American Heart Association

  2. Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results

     –  Study 2 Demonstrated that Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP – –  Over 52-Weeks, Overall Adverse Events in the Bempedoic Acid Treatment Arm were Comparable to Placebo – – Bempedoic

  3. Esperion to Participate in Upcoming Investor Conferences

    ANN ARBOR, Mich., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), today announced that the company will participate in fireside chats at the following conferences: Credit Suisse 28th Annual Healthcare

  4. Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results

    ANN ARBOR, Mich., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the third quarter ended September 30, 2019. "The

  5. Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions

    ANN ARBOR, Mich., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that pooled analyses from four Phase 3 clinical trials of bempedoic acid will be presented at the American Heart Association

  6. Esperion to Report Third Quarter 2019 Financial Results November 6, 2019

    ANN ARBOR, Mich., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report third quarter 2019 financial results on November 6, 2019 before U.S. financial markets open. Bempedoic Acid

  7. Bempedoic Acid Included in Top 10 Medical Innovations for 2020 List

    ANN ARBOR, Mich., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) announced that bempedoic acid was included in the "Top 10 Medical Innovations for 2020" at Cleveland Clinic's 2019 Medical Innovation Summit on

  8. Esperion Completes Patient Enrollment in the Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid

    – 14,032 Patients are Now Fully Enrolled in the CLEAR Cardiovascular Outcomes Trial –– Expect CLEAR Cardiovascular Outcomes Trial to Conclude in the Second Half of 2022 – ANN ARBOR, Mich., Sept. 05, 2019 (GLOBE

  9. Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    ANN ARBOR, Mich., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that, on August 27, 2019, the Compensation Committee of Esperion's Board of Directors granted non-qualified stock options to

  10. Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes

    — Bempedoic Acid / Ezetimibe Combination Tablet Achieved Robust 40% Placebo Corrected LDL-C Lowering —— Provided 25% hsCRP Reduction —— No Worsening of Glycemic Control —— Overall Adverse Events Comparable to Placebo